Free Trial
NASDAQ:MRUS

Merus Q1 2025 Earnings Report

Merus logo
$94.15 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$94.14 -0.01 (-0.01%)
As of 06:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merus EPS Results

Actual EPS
-$2.23
Consensus EPS
-$1.17
Beat/Miss
Missed by -$1.06
One Year Ago EPS
N/A

Merus Revenue Results

Actual Revenue
$8.83 million
Expected Revenue
$9.77 million
Beat/Miss
Missed by -$940.00 thousand
YoY Revenue Growth
N/A

Merus Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Merus' Q3 2025 earnings is scheduled for Thursday, October 30, 2025, with a conference call scheduled on Friday, October 31, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Merus Earnings Headlines

Buy this stock tomorrow
Famed futurist Eric Fry just unveiled his “Sell This, Buy That” strategy — including 7 free trade ideas like a small robotics firm he calls an “upgrade to Tesla,” already sitting on a $23 billion backlog.tc pixel
LifeSci Capital Downgrades Merus N.V. (MRUS)
See More Merus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Merus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Merus and other key companies, straight to your email.

About Merus

Merus (NASDAQ:MRUS) NV is a clinical-stage immuno-oncology company focused on the discovery and development of bispecific antibody therapeutics for the treatment of cancer. Utilizing its proprietary Biclonics® platform, Merus engineers fully human bispecific antibodies designed to engage immune cells and tumor targets simultaneously. The company’s research efforts are aimed at creating novel therapies with optimized potency, selectivity and safety profiles.

The Merus pipeline encompasses multiple Biclonics candidates in various stages of preclinical and clinical development. Key programs are being evaluated in solid tumors and hematological malignancies, with a focus on innovative mechanisms of action that harness T cell redirection, immune checkpoint modulation and co-stimulatory pathways. In addition to its internal development efforts, Merus collaborates with strategic partners to advance select programs and expand its therapeutic reach.

Headquartered in Utrecht, the Netherlands, Merus maintains operations in both Europe and the United States, supporting global clinical trials and regulatory activities. The company completed its initial public offering on the Nasdaq stock market in October 2018, and its research sites extend from the Dutch biotech hub to a dedicated U.S. presence in Boston’s ecosystem.

Merus is led by a management team with extensive experience in oncology drug development and commercialization. Under the leadership of Chief Executive Officer Ton Logtenberg, the company continues to advance its bispecific antibody platform, aiming to deliver transformative treatments for patients with unmet medical needs.

View Merus Profile

More Earnings Resources from MarketBeat